Although targeted therapies can be an effective strategy for treating cancer, the duration of responses to such therapies, for example, BRAF inhibitors (BRAFi), varies substantially and can be dependent on the origin of the primary tumor.5-11. This evidence concerns the gene BRAF and neoplasm.